Francesco Passamonti1,2,3, Barbara Mora4, Daniela Barraco4, Margherita Maffioli4. 1. Department of Medicine and Surgery, University of Insubria, Varese, Italy. francesco.passamonti@uninsubria.it. 2. Hematology, Department of Specialistic Medicine, Ospedale di Circolo, ASST Sette Laghi, Varese, Italy. francesco.passamonti@uninsubria.it. 3. Hematology, Dipartimento di Medicina e Chirurgia, University of Insubria, Via Guicciardini, 21100, Varese, Italy. francesco.passamonti@uninsubria.it. 4. Department of Medicine and Surgery, University of Insubria, Varese, Italy.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to help doctors in the management of patients with post-polycythemia (PPV) and post-essential thrombocythemia (PET) myelofibrosis (MF) facing diagnostic criteria, prognostication, and treatment possibilities. RECENT FINDINGS: Diagnostic criteria of primary myelofibrosis (PMF) have been recently updated from the WHO classification. A clear-cut distinction between pre-fibrotic and overt PMF has been done. Concerning PPV and PET MF, the criteria come from 2008. Prognostication of PMF has been well established on clinical criteria, but recent molecular acquisitions will improve the strategy. For PPV and PET MF, the new MYSEC-PM is helpful for prediction of survival. JAK2-inhibitors and stem cell transplant are the two critical therapeutic approaches in myelofibrosis. Differences between PMF and SMF substantiate the efforts underway to adequately stratify SMF patients with ad hoc prognostic tools and to use such categorization to evaluate available treatment modalities.
PURPOSE OF REVIEW: The purpose of this review is to help doctors in the management of patients with post-polycythemia (PPV) and post-essential thrombocythemia (PET) myelofibrosis (MF) facing diagnostic criteria, prognostication, and treatment possibilities. RECENT FINDINGS: Diagnostic criteria of primary myelofibrosis (PMF) have been recently updated from the WHO classification. A clear-cut distinction between pre-fibrotic and overt PMF has been done. Concerning PPV and PET MF, the criteria come from 2008. Prognostication of PMF has been well established on clinical criteria, but recent molecular acquisitions will improve the strategy. For PPV and PET MF, the new MYSEC-PM is helpful for prediction of survival. JAK2-inhibitors and stem cell transplant are the two critical therapeutic approaches in myelofibrosis. Differences between PMF and SMF substantiate the efforts underway to adequately stratify SMF patients with ad hoc prognostic tools and to use such categorization to evaluate available treatment modalities.
Authors: Elisa Rumi; Francesco Passamonti; Cristina Picone; Matteo Giovanni Della Porta; Cristiana Pascutto; Mario Cazzola; Mario Lazzarino Journal: Blood Date: 2008-09-15 Impact factor: 22.113
Authors: M Maffioli; A Genoni; D Caramazza; B Mora; A Bussini; M Merli; T Giorgino; R Casalone; F Passamonti Journal: Leukemia Date: 2014-01-20 Impact factor: 11.528
Authors: Mohamed Shanavas; Uday Popat; Laura C Michaelis; Veena Fauble; Donal McLornan; Rebecca Klisovic; John Mascarenhas; Roni Tamari; Murat O Arcasoy; James Davies; Usama Gergis; Oluchi C Ukaegbu; Rammurti T Kamble; John M Storring; Navneet S Majhail; Rizwan Romee; Srdan Verstovsek; Antonio Pagliuca; Sumithira Vasu; Brenda Ernst; Eshetu G Atenafu; Ahmad Hanif; Richard Champlin; Paremeswaran Hari; Vikas Gupta Journal: Biol Blood Marrow Transplant Date: 2015-10-19 Impact factor: 5.742
Authors: G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi Journal: Leukemia Date: 2007-08-30 Impact factor: 11.528
Authors: D Barraco; S Cerquozzi; C A Hanson; R P Ketterling; A Pardanani; N Gangat; A Tefferi Journal: Blood Cancer J Date: 2017-03-10 Impact factor: 11.037
Authors: Junshik Hong; Ju Hyun Lee; Ja Min Byun; Ji Yun Lee; Youngil Koh; Dong-Yeop Shin; Jeong-Ok Lee; Sang Mee Hwang; Hyoung Soo Choi; Inho Kim; Sung-Soo Yoon; Soo-Mee Bang Journal: Blood Adv Date: 2019-11-26
Authors: Mariam T Nawas; Jeong-Ok Lee; Jessica Flynn; Molly Maloy; Ann A Jakubowski; Esperanza B Papadopoulos; Christina Cho; Doris M Ponce; Craig S Sauter; Miguel-Angel Perales; Sean Devlin; Sergio A Giralt; Hugo R Castro-Malaspina; Roni Tamari Journal: Bone Marrow Transplant Date: 2022-04-28 Impact factor: 5.174